Your body makes the GLP-1 hormone naturally to help control hunger
Earlier initiation is reshaping patient journeys: Patients are starting GLP1 therapy within weeks of diagnosis, underscoring the need for streamlined access pathways and payer alignment to reduce delays, especially in Medicare populations
Tirzepatide works as a dual agonist, targeting both GLP-1 and GIP receptors, which is why clinical trials have shown it produces greater weight loss than semaglutide alone
to reduce the risk of sustained estimated GFR (eGFR) decline, ESRD, and CV death in patients with type 2 diabetes mellitus and chronic kidney disease Ozempic and Rybelsus tablets: To reduce the risk of major CV events in patients with type 2 diabetes mellitus who are at high risk for these events Wegovy (injection and tablets): In combination with a reduced calorie diet and increased physical activity, to reduce the risk of major adverse CV events in patients with established CV disease and either obesity or overweight Usual Adult Dose for Renal Risk Reduction Ozempic Injection: Initial dose: 0.25 mg subcutaneously once a week for 4 weeks, then 0.5 mg subcutaneously once a week Maintenance dose: After at least 4 weeks on the 0.5 mg dose, increase to 1 mg subcutaneously once a week
Your primary care team at Hopkins MD is here to break it down for you
Pharmacological stimuli are not physiological, and their accuracy is poor
